Market research
CVLB Conversion Labs, Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 703M
- P/E ratio
- Not available
- Analyst target
- 37.5
- Dividend yield
- 0.0%
- Beta
- 1.15
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- ISIN
- Not available
- Market cap
- 703M
- P/E ratio
- Not available
- Analyst target
- 37.5
- Dividend yield
- 0.0%
- Beta
- 1.15
About
About Conversion Labs, Inc
Conversion Labs, Inc. operates as a telemedicine company with a portfolio of online direct-to-consumer brands. The company combines virtual medical treatment with prescription medications and over-the-counter products. Its network of physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. Its brand portfolio comprises of brands targeting market segments, such as hair loss, immune health, men's health, and disaster preparedness. The company was formerly known as Immudyne, Inc. and changed its name to Conversion Labs, Inc. in June 2018. Conversion Labs, Inc. was founded in 1994 and is based in New York, New York.
Research context
Conversion Labs, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CVLB discussion.
5 years, 6 months ago
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.4.
Based on the above factors, Conversion Labs, Inc gets an overall score of 1/5.